curetis (asx: cure) - advancing molecular ......2019/12/01 · dorner et al. (2009); deutsche...

ARES

Technology

Platform

CORPORATE PRESENTATION

December 2019

© 2019 Curetis N.V.1

CURETIS (ASX: CURE) - ADVANCING MOLECULAR MICROBIOLOGY

DISCLAIMER & FORWARD LOOKING STATEMENTS

© 2019 Curetis N.V. 2

This document has been issued by Curetis N.V. (the “Company” and, together with its subsidiaries, the "Group") and does not constitute or form part of and should not be construed as any offer or

invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall any part of it nor the fact of its distribution form part of or be relied on in

connection with any contract or investment decision, nor does it constitute a recommendation regarding the securities of the Company or any present or future member of the Group.

In particular, this document is not an offer of securities for sale in the United States of America. Securities may not be offered or sold in the United States of America absent registration or an exemption

from registration under the U.S. Securities Act of 1933, as amended. Neither this document nor any copy of it may be taken or transmitted into the United States of America, its territories or possessions or

distributed, directly or indirectly, in the United States of America, its territories or possessions.

All information contained herein has been carefully prepared. However, no reliance may be placed for any purposes whatsoever on the information contained in this document or on its completeness. No

representation or warranty, express or implied, is given by or on behalf of the Company or any of its directors, officers or employees or any other person as to the accuracy or completeness of the

information or opinions contained in this document and no liability whatsoever is accepted by the Company or any of its directors, officers or employees nor any other person for any loss howsoever

arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith.

Where third-party information has been used in this document, the source of this information has been identified. The information in this document that has been sourced from third parties has been

accurately reproduced and, as far as the Company is aware and able to ascertain from the information published by that third party, the reproduced information is correct. However, the Company has not

verified the reproduced information and does not guarantee nor bear or assume responsibility for the accuracy and completeness of the information from third-party sources presented in this document.

The information contained in this presentation is subject to amendment, revision and updating. Certain statements, beliefs and opinions in this document are forward-looking, which reflect the Company’s

or, as appropriate, senior management’s current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions

that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the

outcome and financial effects of the plans and events described herein. Statements contained in this document regarding past trends or activities should not be taken as a representation that such trends

or activities will continue in the future. The Company does not undertake any obligation to update or revise any information contained in this presentation (including forward-looking statements), whether

as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak only as of the date of this document.

By attending, reviewing or consulting the presentation to which this document relates or by accepting this document you will be taken to have represented, warranted and undertaken that you have read

and agree to comply with the contents of this notice.


ESTABLISH A WORLD-LEADING ANTIMICROBIAL RESISTANCE (AMR) PRECISION MEDICINE BUSINESS

CURETIS & OPGEN TO COMBINE BUSINESSES

Strategic Rationale

• Establish a world-leading antimicrobial resistance (AMR) precision medicine business

• Broad portfolio of high impact rapid diagnostics and best-in-class AMR bioinformatics

• Leverage combined sales, distribution, bioinformatics and operating infrastructure

Structure of Transaction

• OpGen acquisition of Curetis GmbH for 2.66 million new shares of OpGen common stock, which corresponds to a 72.5% (CURE) to 27.5% (OPGN) relative ownership prior to any additional financing

Financial Considerations

• Combined company positioned for strong growth profile and sustained value creation

• Estimated 2020 combined revenue of $10-15 million, up from an anticipated $5-6 million in 2019

• Target to significantly reduce net loss starting in 2020 and beyond

Subject to approval by OpGen’s and Curetis’ respective regulators, shareholders, and debt financing providers

• Both companies’ Boards of Directors have approved the definitive implementation agreement

• Both companies will seek approval from their respective shareholders in extraordinary general meetings toto be scheduled as soon as practicable

• Provided shareholders and debt holders for both OpGen and Curetis grant approval, the business combination is likely to be completed in early 2020 – closing is subject to successful closing of additional OPGN financing, which will be dilutive to both companies’ shareholders

Companies will pursue their normal course of business until closure of the transaction

For more information, please see: www.curetis.com/investors

http://www.curetis.com/investors


UPDATES AS OF NOV 14, 2019: CONDITION PRECEDENT OF INTERIM FINANCING SUCCESSFULLY MET

CURETIS & OPGEN TO COMBINE BUSINESSES

Debt Holder Approvals

• On 15 October 2019 Curetis debt holder European Investment Bank formally approved the transaction subject to customary closing conditions.

Interim Financing

• On 28 October 2019 OpGen announced successful closing of $9.4 Million underwritten public offering.

• As per the Implementation Agreement between Curetis and OpGen, part of the proceeds form this transaction will be used to (1) complete the business combination with Curetis GmbH; (2) provide short-term funding to Curetis GmbH under an interim financing facility to fund current operations of Curetis’ business.

• The interim financing facility agreement was signed on November 12, 2019 providing Curetis with access to at least US$ 4 million.

S4 Filing

• On 12 November 2019, OpGen filed an S4-Form with the SEC to seek approval of the business combination. Review and approval of the S4 filing are expected in the coming weeks and will be one of the last critical steps before inviting for the shareholder meetings and seeking their approval for the transaction.


FOCUS ON NEAR-TERM STRATEGIC VALUE DRIVERS AND PARTNERING

CONTINUE TO EXECUTE ON REVISED STRATEGY

Submitted to FDA for 510(k) clearance of Unyvero LRT in BAL specimen and with all questions of FDA AI letter answered expecting

near-term clearance decision

Met with expert panel and Chinese National Medical Products Administration (NMPA) to discuss Unyvero HPN submission status

Continued implementation of Ares Genetics’ business with Sandoz, Qiagen and introducing NGS lab services

Entered into definitive agreement with OpGen to combine businesses and supported successful $ 9.4 million OpGen financing and filing

an S4-Form for the approval with the transaction with the SEC

Signed R&D & Option agreement with global IVD Player for Ares Genetics; secured total contract order volume of EUR 3.4 million in 2019

year-to-date for Curetis Group

CURETIS: INTRODUCTION



MOLECULAR MICROBIOLOGY LEADERSHIP THROUGH PROPRIETARY PLATFORMS AND CONTENT

CURETIS‘ VISION

* Unyvero A30 RQ Analyzer in development, latest design concept;

final product may differ

Striving for Molecular Microbiology Leadership

MDx Platforms MDx Content

Low- to High-Plex PCR - Broadest Sample Range Antibiotic Resistance Data Intelligence

Unyvero A50

High-Plex PCRUnyvero A30 RQ

Low- to Mid-Plex PCR

ARESdb

MDx Content & NGS Applications


A COMMERCIAL STAGE MOLECULAR DIAGNOSTICS COMPANY

CURETIS AT A GLANCE

Molecular Diagnostics Company with Focus on Severe Infections

Publicly Listed on Euronext Amsterdam and Brussels

Proprietary Unyvero Platform & AMR Content

Commercial with CE-IVD and U.S.-FDA-cleared Unyvero Products

Growing Global Presence

Attractive R&D Pipeline

Multiple Strategic Partnerships & Partnering Opportunities

UNYVERO: CURETIS’ SOLUTION FOR MOLECULAR MICROBIOLOGY



IMPROVING CLINICAL PRACTICE IN MICROBIOLOGY

UNYVERO PROVIDES RAPID AND ACTIONABLE INFORMATION

Microbiology Culture Pathogen ID: 24-48h Antibiotic Susceptibility: 48-72h +

> Slow

> Manual, laborious, complex

> Often misses hard-to-culture

pathogens & multi-infections

Unyvero 4-5 hPathogen ID

& AMR Markers

> Fast

> Highly automated,

easy-to-use

> PCR - no culture

bias

> Find additional

pathogens and

multi-infections

Culture Unyvero

Time to informed therapy ▲ ▼

Length of stay ▲ ▼

Mortality ▲ ▼

Total costs per case ▲ ▼

Antibiotic Stewardship ▲ ▼

Informed

Therapy

Informed

Therapy

Unyve

ro

Pote

ntial


RAPID INFECTIOUS DISEASE TESTING FOR HOSPITALIZED PATIENTS

UNYVERO IN A NUTSHELL

FAST

COMPREHENSIVE PANELS

FLEXIBLE ON SAMPLE TYPES

EASY TO USE

&

or

*

*

IMPROVE CLINICAL OUTCOMES - SUPPORT ANTIBIOTIC STEWARDSHIP - CREATE HEALTHECONOMIC BENEFITS

* In development, latest design concept; final product may differ


THE UNYVERO ADVANTAGE IN SYNDROMIC TESTING

FOCUS ON MULTIPLEXING AND SAMPLE FLEXIBILITY

* In development, latest design concept;

final product may differ

BioFire

Torch


SIX DISEASE-SPECIFIC CARTRIDGES WITH SYNDROMIC PANELS

BROAD CARTRIDGE PORTFOLIO

Cartridge Indication area Number of targets* Sample types Clearance status

HPN** Severe cases of Pneumonia 48 targets****,

pathogens (29) and

antibiotic resistance markers (19)

Sputum, broncho-alveolar lavage, tracheal aspirate CE-IVD marked

Singapore (HAS)

Thailand

Malaysia

LRT Lower Respiratory Tract Infections 46 targets****,

pathogens (36) and


Tracheal aspirates

LRT Application for BAL under FDA review

U.S. FDA cleared

ITI Severe cases of Implant and Tissue Infections 102 targets,

pathogens (85) and


Sonication fluid, swabs, striche, tissue, pus, aspirate/exudate, etc. CE-IVD marked

BCU*** Bloodstream infections 103 targets,

pathogens (86) and


Positively flagged blood cultures CE-IVD marked

Singapore (HAS)

Thailand

IAI Severe Intra-Abdominal Infections 130 targets,

pathogens (105),

toxins (3) and


Paracentesis fluids, biliary fluids, peritoneal fluids, drainage fluids, retroperitoneal

fluids, pus, swabs, samples from positively flagged blood culture bottles

inoculated with other fluids than blood (IAI fluids such as ascites)

CE-IVD marked

UTI Severe cases of Urinary Tract Infections 103 targets,

pathogens (88) and


Midstream urine, suprapubic aspiration, tissue CE-IVD marked

*As of 31 July 2018 **HPN: Hospitalized Pneumonia ***BCU: Blood Culture Application

****Difference between HPN and LRT due to different reporting requirements between CE-IVD and

U.S. FDA-cleared products


U.S. AND EUROPEAN MARKET WITH HIGH UNMET MEDICAL NEED ADDRESSABLE THROUGH HOSPITAL-FOCUSED SALES CHANNELS

CURETIS‘ MARKET POTENTIAL

The current Unyvero portfolio and pipeline of cartridges target over 9 million patients annually in EU and U.S.

with additional upside in Asia

2,329,0001

2,128,2152

393,81031,976,1304

1,312,7005

1,600,0006

> 9.73M

cases1 CDC (2010); ECDC (2008); Chalmers et al. (2014)

2 Margolis et al. (2011); American Diabetes Association (2014); Diabetes Deutschland (2012); Richard et al. (2011); Livesly and Chow (2002);

Dorner et al. (2009); Deutsche Gesellschaft für Verbrennungsmedizin (2014); Mayhall (2003); Klevens et al. (2007) in Jhung (2009); Geffers

(2001); Brun-Buisson (2011); Michelotti et al. (2012); Sunderlin (2006)

3 Martin (2012); Statista (2015); Dellinger et al. (2013)

4 HCUP (2013); CDC (2010)

5 Martin (2012); Statista (2015)

6 ECDC (2013), Klevens et al. (2002)


COMBINATION OF DIRECT SALES & DISTRIBUTION PARTNERS

DUAL COMMERCIAL STRATEGY

Expanding Global Commercial

Reach

> Direct sales in the U.S.

> Switched key EU markets from direct

sales to distribution model

> 18 distribution partners covering 43

countries in EU, ME, and Asia

> Continuously expanding partner network

Direct

Partner


STARTING WITH 11 EU COUNTRIES – OPTION TO EXPAND PARTNERSHIP TO FURTHER MARKETS

PAN-EUROPEAN DISTRIBUTION BY MENARINI DIAGNOSTICS

Menarini Diagnostics

Partnership

> Covers entire Unyvero A50 product line

> Initial countries: BE, CH, DE, ES, FR, IT,

LU, NL, PT, SE, UK

> Option to expand partnership to further

countries

> Launched partnership at ECCMID 2019

> Customer hand-over completed in

Q2-2019

A. Menarini Diagnostics

Other Distribution Partners


INSTRUMENT PLACEMENTS AND CARTRIDGE UTILIZATION DRIVE SALES

CURETIS‘ BUSINESS MODEL

“Razor / Razor-Blade“

Business Model

> Systems placed under reagent-rental / rent-to-own in direct sales markets

> ~ EUR 40,000 investment per installed system to be recouped by cartridge sales over time

> Target customers using between 200-600 cartridges per year

> Customers utilizing growing menu of cartridges over time

> 1-2 cartridges/day translate to approx. EUR 30,000-75,000 recurring revenue potential per end-customer per year

* Diagnosis-Related Groups

Hospital Stakeholder

Benefits

Microbiology Lab- 24/7 day operation- Minimal hands-on-time- Workflow efficiency

ICU & Clinicians- Fast, actionable results- Point of need- Antibiotic stewardship

Finance & Admin- Improved health economics- Increase margins on DRGs*- Improve patient throughput


CARTRIDGE MANUFACTURING IN HOUSE – INSTRUMENTS OUTSOURCED TO CONTRACT MANUFACTURER

BALANCED MANUFACTURING SET-UP

Cartridges

> Experienced manufacturing and QC teams

> ISO 13485:2016 certified and FDA-inspected (Q1/2019)

> Dedicated 1,600 m² facility for cartridge manufacturing

Two ISO-8 and one ISO-7 clean-rooms

Three QC laboratories

Scalable capacity

Instruments

> Unyvero Systems manufactured by Zollner Elektronik (Top-tier EMS Provider)

> Hundreds of thousands cartridges manufactured to date > Scalable operational capacity currently estimated at up to 1 million cartridges (based on 24/7 processing) annually > Seamless supply chain management

OUTLOOK: GEOGRAPHIC EXPANSION



OFFERING UNIQUE ADVANTAGES FOR SEVERE BACTERIAL PNEUMONIA

UNYVERO LRT – CUTTING-EDGE MDx FOR THE U.S.

UNIQUE PRODUCT

FOR BACTERIAL

PNEUMONIA

Most comprehensive panel secifically tailored to bacterial

pneumonia delivering unique clinically actionable insights

Only molecular pneumonia panel to cover penicillin resistance

Sample-to-answer direct from native specimen

Broadest coverage of carbapenem resistance

Multiple strong

clinical data

sets presented

at ASM 2019


INITIAL FOCUS ON HOSPITALS AND LTACS

UNYVERO LAUNCH IN THE U.S.

LAUNCHED WITH FOCUS ON HOSPITAL AND

LTAC* MARKETS:

> Initially targeting about 1,000 Tier 1 and Tier 2 hospitals based on # of

ICU beds and high incidence of pneumonia in each of the Territory Sales

Manager territories

> Explore and qualify LTAC facilities associated with large hospital

networks

> Seek early adopters that embrace rapid results over current

methodology and that may not require extensive patient outcome study

support

> Target hospitals with strong antibiotic stewardship programs that may

gravitate to 2016 IDSA VAP/HAP guidelines

*LTAC = Long term acute careTarget influential KOLs per

region for early adoption


STRONG FUNNEL OF COMMERCIAL OPPORTUNITIES FOR UNYVERO LRT

U.S. COMMERCIALIZATION

Field-based agent/expert

Curetis USA Inc. HQ

> Built solid funnel of sales opportunities

> Focus on early-adopter accounts

> As of end of Q3-2019 15 Unyvero A50 Analyzers

installed

> Numerous commercial evaluations ongoing

> First evaluations successfully completed

> Multiple near-term opportunities for additional

evaluations


SUBMITTED UNYVERO LRT FDA FILING FOR BAL SAMPLES IN JULY 2019

PLANNED U.S. UNYVERO PORTFOLIO EXPANSION

LRT for Use with BAL Samples

> LRT optimized for use with bronchoalveolar

lavage (BAL) samples

> Successfully completed clinical validation trial

with 90.1% (94.7%) sensitivity at 98.4% (97.9%)

specificity in prospective (retrospective) cohorts

> Significant performance improvement in

sensitivity compared to 2016 FDA trial

> FDA submission in July – interactive review

based on FDA AI letter ongoing

IJI Invasive Joint Infection Cartridge

> Potential next Application Cartridge for the

U.S. market

> Synovial fluid sample collection ongoing at

multiple sites in the U.S.

> Sample stability study completed at 3 trial

sites with additional collection ongoing

> Further development subject to funding

and/or partnering


CHINA REPRESENTS A STRONG POTENTIAL GROWTH MARKET FOR CURETIS

GEOGRAPHIC EXPANSION: CURETIS IN CHINA

UPDATE ON CHINA

> Submitted for approval of Unyvero Instrument and Unyvero HPN Cartridge based on US-FDA and EU CE-IVD clinical

study data in February 2019

> NMPA hosted expert panel meeting that discussed Unyvero HPN submission in July 2019 – final minutes pending

> Expect possible NMPA approval and subsequent commercial impact from 2020 onwards

Distribution Agreement with Beijing Clear Biotech (BCB)

> Covers China, Taiwan, and Hong Kong (via Technomed)

> BCB will conduct and fully fund all clinical trials for NMPA approval

> BCB commited to minimum purchase of Unyvero Systems (360) and

Application Cartridges (1.5 Mio) over 8 year period from NMPA approval

> Revenue potential implied would be > EUR 30 mio p.a. in years 6 to 8

on top of the > 60 Mio EUR cumulative revenue in years 1 to 5

MEDIUM TERM UPSIDE POTENTIAL THROUGH PRODUCT PORTFOLIO DEVELOPMENT



EXPANSION TO LOW- AND MID-PLEX APPLICATIONS & ATTRACTIVE PARTNERING OPPORTUNITY

UNYVERO A30 RQ: SMALL, FAST, QUANTITATIVE

A30 RQ: Key Design Features*

> Low- to Mid-plex with 5-30 targets

> Sensitive and quantitative real-time PCR technology

> Processes any native samples

leveraging Unyvero Lysator when required

> Rapid 45-90 min time-to-result

> Easy to use with 2-5 min hands-on time

> Small footprint

> Point-of-care capable

> Low COGS Target: >66% reduction vs. current high-plex

Unyvero (Instrument & Consumables) at scale

> Modular concept for full integration with other Unyvero

modules or stand-alone operation

* in development, latest design concept; final product may differ. * in development, latest design concept; final product may differ.


TARGET DEVELOPMENT COMPLETION AND A30 PLATFORM READY FOR PARTNERING IN 2020

UNYVERO A30 RQ: R&D PROGRESSING TOWARDS PARTNERING

Current Development Status

> First multiplex PCR successfully demonstrated on fully

functional prototypes in tech due diligence for potential partners

> Manufacturing aspects fully specified and in development or

implementation phase

> Expect to progress development in H2-2019 and H1-2020 for

full V&V readiness for licensing partner‘s assays

Status of Partnering Discussions

> Curetis is actively engaged in several potential partnering and

licensing discussions. Deal making will depend on finalizing

instrument and cartridge development over the coming quarters

subject to successful financing to fund such final development

steps.

28

DATA INTELLIGENCE FOR NEXT-GEN MOLECULAR MICROBIOLOGY

ARES GENETICS TECHNOLOGY PLATFORM

Unique Content for

Infectious Disease Diagnostics

AI-powered AMR Knowledgebase & Decision Support

Pharma Services

ARESdb & ARES Technology Platform

> Likely the world’s most comprehensive database on the genetics of AMR covering

> 30 years of emerging antibiotic resistance

> Advanced bioinformatics and artificial intelligence solutions to inform infectious

diagnostics and therapeutics covered by a broad IP portfolio

> Collaboration-based business model to fast-track digital AMR solutions –

validated through partnerships with Sandoz, Qiagen, and global IVD and NGS

companies

> Launched NGS services by ARESlab Vienna for molecular microbiology and

started offering 1st and 2nd Generation ARESupa – Universal Pathogenome Assay

© 2019 Curetis N.V.

NGS-based Solutions for

Molecular Microbiology


FAST-TRACK TO ESTABLISHING AN NGS-BASED MOLECULAR MICROBIOLOGY FRANCHISE

ARES GENETICS BUSINESS EXECUTION

2017

2013/14 2018

R&D initiation by Ares

Mgmt Team at SIEMENS

German Innovation

Award

“The Digital Microbe”

R&D Grant (~ € 1,6 M)

Go Silicon Valley Award

“AI-powered NGS”

R&D Grant (~ € 1,3 M)

2019

Recognized as Top 30 AI

Start-up by Forbes

Grant of Key Patent on

Genetic Testing

Establishing of

Ares Genetics

Broad Collaboration

Launch of Pharma

Partnering Program

Pharma Partnership

Licensing DealLaunch of Ares NGS

Service Laboratory

> € 2 M contract volume secured

in 2019.

100 % Accuracy for Pathogen ID as

well as for > 50 Pathogen / Drug

Combinations in blinded feasibility

Study as part of a multi-phase Partnership with undisclosed

global IVD Leader.


BUILDING A LEADING NEXT-GEN MOLECULAR MICROBIOLOGY FRANCHISEWITH GLOBAL PLAYERS

ARES GENETICS PARTNER ECO SYSTEM

StrategicCollaboration with

global NGS Leader

Strategic Collaboration with

global BioinformaticsLeader

~ € 3 Mio total project volume of co-

funded R&D projects

IVD Product development with

global DiagnosticsLeader

Strategic Collaboration with

global Pharma Leader

Globally Leading

IVD Company

Initial Technology Development by

Mgmt Team


LEADER IN MOLECULAR MICROBIOLOGY WITH MULTIPLE PLATFORMS, PRODUCTS, AND

DIFFERENTIATED CONTENT AND MANY ATTRACTIVE PARTNERING OPPORTUNITIES

WHY CURETIS? STRATEGIC OPTIONALITY WITH OPGEN!

Strong Technology Base: Broad patent portfolio covering key aspects of sample preparation, nucleic acid amplification and detection, and

molecular microbiology content

Versatile Unyvero MDx Platform: Sample-to-Answer MDx allowing broad range of applications: from 5+ target triage-screen, via 10 to 30

target rapid tests to 100+ target syndromic panels

Validated Products in an Attractive Market: Unique Unyvero System and Applications address high unmet needs in some of the most

prevalent infectious disease indications in hospitalized patients

Unique U.S. Application: Unyvero LRT, first ever pneumonia MDx panel cleared by U.S. FDA with anticipated clearance also for broader

sample range in the coming months

Multiple strategic partners and attractive Partnering Opportunities: Further near-, mid- and long-term partnering opportunities beyond the

core business in the rapidly growing market for PCR and NGS-based Molecular Microbiology

Next Generation Molecular Microbiology: Growing business with unique data-driven, NGS-based solutions for pharma and diagnostics by

Ares Genetics

Combining Business with OpGen: Establish a world-leading antimicrobial resistance (AMR) precision medicine business

APPENDIX



COMBINES DECADES OF OPERATIONAL AND COMMERCIAL EXPERIENCE

STRONG MANAGEMENT BOARD

Dr. Achim Plum,

CBO Curetis N.V. & Managing

Director Ares Genetics GmbH

~20 years in commercial roles in

IVD/MDx, Biotech & Pharma

(ex Siemens, Epigenomics, Schering)

Oliver Schacht, Ph.D.

CEO Curetis N.V.

~20 years in MDx and biotech (ex

CFO Epigenomics AG and CEO

Epigenomics, Inc.)

Johannes Bacher,

COO Curetis N.V. & Co-Founder

Curetis

~20 years R&D and management

experience

(ex Hewlett Packard, Agilent

Technologies, Philips)


EXPERIENCED AND DIVERSE NON-EXECUTIVE SUPERVISORY BOARD

SUPERVISORY BOARD

William E. Rhodes, III

Chairman of the Board;

Chairman of Remuneration

Committee;

ex Becton Dickinson,

USA

Dr. Werner Schäfer

Vice chairman;

Chairman of Nomination &

Appointment Committee;

ex COO Roche Diagnostics,

Germany

Mario Crovetto

Chairman of the Audit Committee;

ex CFO Eurand / Recordati,

Italy

Prabhavathi Fernandes, Ph.D.

Member of the Board;

ex CEO of Cempra Pharmaceuticals

Inc., Bristol-Myers Squibb

Pharmaceutical Research Institute,

Abbott Laboratories,

USA

Dr. Rudy Dekeyser

Member of the Board;

LSP,

Belgium

Dr. Nils Clausnitzer

Member of the Board;ex VWR International LLC / VWR

GmbH

ex QIAGEN, Olympus, Abbott

Germany


KEY FACTS AT A GLANCE

CURETIS OVERVIEW

• Listed on Euronext Amsterdam and Brussels

• Ticker symbol: CURE

• IPO: 11th Nov 2015

• No. of shares outstanding: 25,623,129*

• Current market capitalization: approx. €13.6 million**

• Share ownership >3% as of 30 Nov 2019

* As of 30 Nov 2019

** Source: Euronext as of 30 Nov 2019

16.6%

7.8%

3.8%

3.7%

68.1%

LSP Curetis Pooling

Milaya Invest

KfW (Federal Republic of Germany)

Roche Finanz AG

Free Float


KEY FIGURES 9M-2019 (UNAUDITED)

FINANCIAL REPORTING

9M-2019 Report and Business UpdateThe full Third Quarter and 9-Month Business and

Financial Update is available from Curetis’ website at:

https://curetis.com/investors/#financial-reports

**Acccess to Interim FinancingAs per the interim financing facility agreement

with OpGen singed on 12 November 2019, Curetis has

access to at least an additional US$ 4 million funding

over the coming months towards the closing of the

business transaction with OpGen.

Key Figures 9M-2019 (unaudit)

For the first 9 months ended 30 September 2018 2019

Global Installed Base as of 30 September (Analyzers) 166 165

Revenue (in thousand EUR) 1,191 1,383

Order Volume received (in thousand EUR) 1,100 3,400

Net cash and cash equivalent at the end of the period

(in thousand EUR)

- Net cash & cash equivalents at the beginning of the year

- Net decrease in cash & cash equivalents

- Effects of exchange rate changes of cash & cash

equivalents

5,541

16,311

-10,926

156

3,049

10,279

-7,317

87

https://curetis.com/investors/#financial-reports


Curetis N.V.

Max-Eyth-Str. 42

71088 Holzgerlingen | Germany

Tel.:+49 (0)7031/49195-10

E-Mail: [email protected]

www.curetis.com

curetis (asx: cure) - advancing molecular ......2019/12/01 · dorner et al. (2009); deutsche...

Documents